D.3.2 Product code where applicable13: ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
193	プラダー・ウィリ症候群	1

193. プラダー・ウィリ症候群

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-003062-13-IT (EUCTR)	20/03/2019	07/10/2020	A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an una ...	A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an una ...	Prader-Willi Syndrome MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, ...	Product Name: D.3.2 Product code where applicable13: Product Code: [AZP-531]	Millendo Therapeutics SAS	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 2	France;United States;Canada;Belgium;Spain;Netherlands;United Kingdom;Italy

First Previous1Next Last